Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity Hospital, Bordeaux

About this trial

This retrospective multicentre cohort evaluates the agreement of measurable residual disease (MRD) detection in acute myeloid leukaemia (AML) using two flow-cytometry gating approaches. Manual expert gating is compared with an unsupervised FlowSOM clustering algorithm across post-induction and post-consolidation samples from 50 adults and 10 paediatric patients treated at Bordeaux University Hospital. The primary hypothesis states that unsupervised gating detects MRD ≥ 0.1 % with sensitivity and specificity comparable to manual gating.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed diagnosis of acute myeloid leukaemia per ELN 2022

Age ≥ 18 years (adult cohort) or 0-20 years (paediatric cohort)

Inclusion in DATAML Bordeaux database or paediatric haemato-oncology records

Available flow-cytometry MRD data post-induction and post-consolidation 1

Disqualifiers

AML subtypes M3, M6 or M7

Acute leukaemia of ambiguous lineage

Missing or unusable flow-cytometry files for required time points

Trial population

Consecutive adult and paediatric patients diagnosed with ELN-defined AML at Bordeaux University Hospital between 2010 and 2024, for whom routine multiparameter flow-cytometry MRD assessments post-induction and post-consolidation 1 are available

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Conventional gating

    Diagnostic test

    Manual expert gating of multiparameter flow-cytometry data for MRD

  • Automated gating

    Diagnostic test

    Unsupervised FlowSOM gating of multiparameter flow-cytometry data for MRD

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Adult AML cohort2 interventions
Group B: Paediatric AML cohort2 interventions

Trial outcomes

Primary outcomes

1

Concordance of MRD ≥ 0.1 % between manual gating and unsupervised FlowSOM gating

Sensitivity, specificity, positive and negative predictive values, Cohen and Fleiss kappa statistics comparing the 3 methods on paired samples

Time frame
up to 8 weeks after initiation first cycle of intensive therapy and after initiation of second cycle of intensive therapy

Secondary outcomes

1

Concordance of flow-cytometry MRD (both methods) with molecular MRD

Sensitivity, specificity, positive and negative predictive values, Cohen and Fleiss kappa statistics comparing the 3 methods on paired samples

Time frame
up to 8 weeks after initiation first cycle of intensive therapy and after initiation of second cycle of intensive therapy
2

Agreement of MRD 0.01-0.1 % between manual and unsupervised gating

Bland-Altman limits of agreement and Pearson or Spearman correlation coefficients calculated from log-transformed MRD percentages to assess agreement between both gating methods in the low MRD range

Time frame
up to 8 weeks after initiation first cycle of intensive therapy and after initiation of second cycle of intensive therapy
3

Concordance of flow-cytometry MRD (both methods) with molecular MRD

Kaplan-Meier survival analyses and multivariable Cox regression models used to compare relapse-free survival (RFS) and overall survival (OS) according to MRD detection method

Time frame
From diagnosis up to 60 months
4

Inter-operator reproducibility of manual gating

Intra-class correlation coefficients and Fleiss kappa statistics calculated across three independent operators performing manual gating on the same flow-cytometry MRD files

Time frame
up to 8 weeks after initiation first cycle of intensive therapy and after initiation of second cycle of intensive therapy

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: